Clinical trials: Systemic Lupus, open to volunteers
System Lupus Erythematosus(SLE)
Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis.
This study will identify the level of serum Riboneuclease 1 in systemic lupus patients and compare between its level in lupus nephritis and non nephritis.
- Trial name
- NCT07763821
- Volunteers
- 128 people
- Sponsor
- Assiut University
Systemic Lupus Erthematosus (SLE)
KN5501 Cell Injection for Refractory SLE(CLEAR)
The goal of this clinical trial is to learn about the safety, pharmacokinetics and pharmacodynamics profile of KN5501 cell injection in adults with systemic lupus erythematosus(SLE).
- Trial name
- CLEAR (NCT07358988)
- Testing
- KN5501 cell injection
- Where
- 6 sites in China
- Volunteers
- 36 people
- Sponsor
- Ruitherapeutics Co., LTD
Systememic Lupus Erythematosus, Systemic Sclerosis (SSc)
Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies
Systemic autoimmune diseases associated with type I interferon (IFN-I) dysregulation, such as systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type…
- Conditions
- Systememic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathies, Connective Tissue Diseases
- Trial name
- SAFRAN (NCT07837986)
- Testing
- biological samples
- Where
- 3 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Systemic Lupus Erythematosus (SLE)
An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus
The purpose of the study is to evaluate the safety and efficacy of CD20xCD3 T-cell engager (GB261) in patients with refractory seropositive systemic lupus erythematosus.
- Trial name
- NCT06945068
- Testing
- GB261
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Systemic Lupus Erythematosus (Sle)
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
Study Description: Systemic lupus erythematosus (SLE) occurs predominantly in women and is driven by type I interferon dysregulation and neutrophil hyperresponsiveness.
- Trial name
- NCT06032923
- Testing
- Nicotinamide Riboside
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lupus Erythematosus, Systemic
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus…
- Trial name
- NCT06897930
- Testing
- AZD0120, Cyclophosphamide, Fludarabine
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus
Transcutaneous Vagus Nerve Stimulation in SLE
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease. Joint and muscle pain and fatigue are extremely common among patients and contribute to a reduced quality of life.
- Trial name
- TvSSLE (NCT06987565)
- Testing
- Active vagus nerve stimulation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Northwell Health
Systemic Lupus Erythematosus
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
To evaluate the efficacy and safety of CM313(SC) injection in systemic lupus erythematosus(SLE)
- Trial name
- NCT06791772
- Testing
- CM313 injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Keymed Biosciences Co.Ltd
Systemic Lupus Erythematosus
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous CD19-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
- Trial name
- NCT07331467
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Multiple Sclerosis (MS), Myasthenia Gravis (MG)
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard…
- Conditions
- Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus
- Trial name
- NCT07676266
- Testing
- CD20/BCMA-directed CAR-T cells Autologous 2nd generation
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- ELOWEN-1 (NCT07332481)
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 74 sites in United States, Australia and 18 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Systemic Lupus Erythematosus
Intervention to Improve Communication and Medication Adherence in Lupus
CO-LEAD is an intervention to improve patient-provider communication and medication adherence among patients with systemic lupus erythematosus (SLE).
- Trial name
- CO-LEAD (NCT06458075)
- Testing
- CO-LEAD
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Duke University
SLE - Systemic Lupus Erythematosus
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
This study is a randomized, double-blind, placebo-controlled Phase I clinical trial featuring single and multiple ascending doses.
- Trial name
- NCT07177911
- Testing
- CC312
- Where
- China
- Volunteers
- 32 people
- Sponsor
- CytoCares Inc
Lupus Nephritis, ANCA-associated Vasculitis
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
This study is a single-center, open-label, dose-escalation exploratory clinical trial, expected to enroll 6 to 12 participants. It will use a BOIN (Bayesian Optimal Interval) design for dose escalation, with four predetermined…
- Conditions
- Lupus Nephritis, ANCA-associated Vasculitis, Membranous Nephropathy - PLA2R Induced, IgG4-Related Diseases
- Trial name
- NCT06285279
- Testing
- FKC289
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Nanjing University School of Medicine
Systemic Lupus Erythematosus, Lupus Nephritis
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Trial name
- NCT06121297
- Testing
- CABA-201
- Where
- 23 sites in United States, Canada and 1 more
- Volunteers
- 28 people
- Sponsor
- Cabaletta Bio
Lupus Erythematosus
Identification of Modifiable Sleep-related Factors in Patients With Systemic Lupus Erythematosus.
Background: Sleep quality is a key determinant of physical and mental health, with important implications for immune regulation, psychological well-being, and overall quality of life.
- Trial name
- NCT07483541
- Testing
- Adults with systemic lupus erythematosus
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia (AIHA)
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
This is an open lable and single arm study designed to evaluate the safety, PK and PD of Arnovie101 in B cell-mediated Autoimmune Disease
- Trial name
- NCT07629596
- Testing
- Arnovie101 Infusion Intravenous
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Circunited BioPharma (Shenzhen) Co., Ltd.
Refractory Systemic Lupus Erythematosus
IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)
The study is a single-arm, open-label clinical trial intended to recruit 6 refractory SLE subjects who meet the inclusion and exclusion criteria.
- Trial name
- NCT06513429
- Testing
- IM19 CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Peking University Third Hospital
Rheumatoid Arthritis, Pemphigus Vulgaris
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris…
- Conditions
- Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
- Trial name
- IRIS-RD-01 (NCT06581562)
- Testing
- AB-101, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- IRIS Research and Development, LLC
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- NCT07355218
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 70 sites in United States, Australia and 18 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.